The 20-F confirms a clean operational turnaround (positive operating income, working capital surplus, stable margins) but is overshadowed by a $13.4M uncertain tax liability from contesting 280E, which could require cash outflows if tax authorities prevail. The Schedule III rescheduling of medical marijuana in April 2026 may eventually reduce tax burden for that portion of the business. Monitor IRS guidance on 280E applicability and any cash tax settlements. The NCIB indicates management view of undervaluation, providing a modest floor.
Price Chart
Executive Summary
C21 Investments filed Form 20-F for FY2026 (year ended March 31, 2026), reporting revenue of $32.6M (+8.3% YoY) and operating income of $2.3M (+78% YoY). The company generated positive operating cash flow of $1.4M and improved to a working capital surplus of $1.9M from a deficit of $0.5M. However, a $4.6M income tax expense (driven by the company's position that IRC Section 280E does not apply, creating $13.4M in uncertain tax liability) kept net loss at $3.2M. The filing also confirms the settlement of the EFF litigation for $2.4M cash + shares, and notes the April 2026 federal rescheduling of medical marijuana to Schedule III.
Key Facts
- FY2026 revenue $32.6M, +8.3% YoY from full year of third dispensary (acquired June 2024 for $3.5M)
- Operating income $2.3M, +78% YoY (FY2025: $1.3M)
- Gross margin stable at 41.7%
- Adjusted EBITDA $5.5M, +13% YoY (FY2025: $4.9M)
- Net loss $3.2M due to $4.6M income tax expense driven by 280E-related uncertain tax position ($13.4M liability)
- Working capital surplus $1.9M vs ($0.5M) deficit prior year; cash $2.2M
- Free cash flow from continuing ops $1.4M unchanged YoY
- EFF litigation settled for $2.4M cash over 19 months + 555,793 shares; $1.1M paid in FY2026
- $13.4M uncertain tax position as company contests 280E applicability
- NCIB on track; 479,500 shares repurchased in FY2026 at avg $0.21
- April 2026: DEA rescheduled FDA-approved/state-medical marijuana to Schedule III (adult-use unchanged)
Financial Impact
Revenue +8.3% to $32.6M; operating income +78% to $2.3M; net loss narrowed to $3.2M from $4.0M. Cash from operations $1.4M. Uncertain tax position grew to $13.4M.
Risk Factors
- IRS may challenge the $13.4M uncertain tax position; adverse outcome could require material cash payments exceeding $2.2M current cash
- Adult-use marijuana remains Schedule I, 280E continues to apply to adult-use operations
- Legalization/enforcement landscape remains uncertain; Rescheduling Rule does not cover adult-use
- Material weakness in internal controls over financial reporting persists
- CEO/10%-owner Sonny Newman is largest shareholder and related-party leases ($4.3M liability) create governance risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001062993-26-003168 |
| Exhibit: exhibit15-1.htm | 0001062993-26-003168 |
| Exhibit: exhibit4-1.htm | 0001062993-26-003168 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | 6-K | $0.2590 awaiting T+20 | awaiting T+20 | — | — |
Jun 15, 2026 15w ago | 6-K | $0.2490 $0.2390 | ▼ −4.02% | ▼ −3.88% | — |
Jun 12, 2026 16w ago | 20-F | $0.2700 $0.2388 | ▼ −11.56% | ▼ −12.82% | — |
Jun 12, 2026 16w ago | 6-K | $0.2700 $0.2388 | ▼ −11.56% | ▼ −12.82% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access